SPEARHEAD-3 Pediatric Study
A phase 1/2 trial of Afamitresgene autoleucel in osteosarcoma, run by USWM CT, LLC, now recruiting.
Overview
SPEARHEAD-3 Pediatric Study is a phase 1/2 interventional study registered as NCT05642455 by USWM CT, LLC, with 20 participants planned, started 2023-09-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: Afamitresgene autoleucel. Conditions listed: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma. No results are recorded here; the registry entry is the source.
Setting
A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors
Phase
Phase 1/2
Sponsor
USWM CT, LLC
Registry
Enrolled
20